News | April 26, 2024
Merck 1Q 2024 sales up 9% to US$ 15.8 billion
Sales reflect continued strong growth in oncology and vaccines
Sales reflect continued strong growth in oncology and vaccines
Submission based on results from pivotal phase III trial showing all primary endpoints met
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Application based on results from the TROPION-Breast01 Phase III trial
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Acquisition of exclusive commercialization rights for European markets
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Subscribe To Our Newsletter & Stay Updated
